Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
Adicet Bio (NASDAQ: ACET), a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has announced its participation in the upcoming Jefferies Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details of the event are as follows:
Date: Wednesday, June 4, 2025
Time: 4:20 p.m. ET
The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521914133/en/
Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com
Penelope Belnap
Precision AQ
penelope.belnap@precisionaq.com
Source: Adicet Bio, Inc.